Generex has been awarded a new patent for its buccal drug delivery platform technologies.
The Canadian Intellectual Property Office has granted Generex with Canadian Patent No. 2,354,148, titled “Aerosol Formulations for Buccal and Pulmonary Application.”
The receipt of the new patent has increased the number of patents that are related to the company's buccal drug delivery platform technologies to 162.
Generex currently have a further 101 pending patent applications in the field.
Rose Perri, Generex’s chief operating officer, said: "We continue to augment the breadth and depth of the intellectual property protection for our drug delivery platform."
She said the company is now planning to kickstart the platform’s commercialision opportunities for insulin and other active pharmaceutical ingredients (APIs).